Seedlabs

Perioperative-or-Surgery-Alone Decision Aid for Cisplatin-Ineligible Bladder Cancer

A tablet tool helping bladder cancer patients choose between surgery alone or surgery with medication.

A visit-time tablet tool for newly diagnosed muscle-invasive bladder cancer patients who cannot take cisplatin, showing the quantified choice between going straight to cystectomy or adding perioperative enfortumab vedotin plus pembrolizumab: 2-year event-free survival of 74.7% vs 39.4% and a 57.1% vs 8.6% chance the tumor is completely gone at surgery, against severe side effects in 71.3% vs 45.9% and roughly a year of treatment.

MedicineBladder and Urothelial Cancer Treatments
Metabolism and Genetic DisordersOncology shared decision-making and patient engagement in urologic oncology clinics

Concept

A shared decision aid delivered on a tablet in the urology or medical oncology exam room, for adults with newly diagnosed muscle-invasive bladder cancer who are ineligible for or decline cisplatin chemotherapy. The tool walks the patient and clinician through the now-quantified choice between proceeding directly to radical cystectomy with pelvic lymph-node dissection, or adding perioperative enfortumab vedotin plus pembrolizumab (3 neoadjuvant cycles, surgery, then the remaining adjuvant cycles — 9 enfortumab vedotin and 17 pembrolizumab cycles in total, roughly a year of treatment). Plain-language visuals show: 2-year event-free survival 74.7% vs 39.4%; 2-year overall survival 79.7% vs 63.1%; chance of pathologic complete response (no viable tumor at surgery) 57.1% vs 8.6%; and the cost — severe (grade 3 or higher) adverse events in 71.3% vs 45.9% of patients, with 45.5% severe drug-related events. A short values exercise (survival vs toxicity tolerance, treatment duration, visit burden) produces a one-page summary for the chart and informed consent.

Why now

Paper [0] (phase 3, n=344, median follow-up 25.6 months) is the first evidence that this population — which previously had no perioperative option and went straight to surgery — has a regimen that nearly halves the risk of an event or death (hazard ratio 0.40) and of death (hazard ratio 0.50). The trade-off is genuinely close for many patients: severe toxicity runs 71.3%, therapy spans about a year, and surgery itself proceeds at essentially the same rate whether or not the drugs are given (87.6% vs 89.7%). A structured, quantified decision aid is the natural product to turn these headline results into individualized choices at the point of care.

Written by GLM · 12 Oct 2026

AI assessment

Backed by 1 paper85

A highly focused, evidence-backed decision aid that translates a specific Phase 3 trial into a clinical tool for a high-stakes medical trade-off.

Evidence strength
5/5
The idea is directly derived from a Phase 3 trial with specific, quantified outcomes (EFS, OS, pCR, and toxicity) that provide all the necessary data for the tool.
Market pull
4/5
Urologic oncologists face a genuine challenge in communicating these complex trade-offs to patients, and pharma sponsors have a strong incentive to ensure the regimen is correctly adopted.
Novelty & moat
2/5
The mechanism is nearly identical to the existing EGFR-Mutated NSCLC decision aid in the catalog, representing a variant applied to a different cancer type.
Feasibility
5/5
Building a tablet-based decision aid with static data and a simple values-exercise logic is a low-complexity software task.
Wedge clarity
5/5
The wedge is extremely sharp: a single, specific patient population (cisplatin-ineligible MIBC) facing one specific treatment choice.
Simplicity / focus
5/5
The product is a single-purpose tool with a clear input (patient values) and output (summary report), avoiding any platform bloat.

Scored by Gemma 4 · 12 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Bladder Cancer Advocacy Network (BCAN)organization

    The main US bladder cancer patient advocacy group; its community of cisplatin-ineligible patients now faces a brand-new, toxicity-laden perioperative option and needs exactly this plain-language quantified trade-off tool.

  • Cleveland Clinicorganization

    A high-volume multidisciplinary bladder cancer program that can use the tool to standardize counseling across urologists and medical oncologists for a newly complex decision.

  • Merck & Co.company

    Maker of pembrolizumab and sponsor of the trial; a validated shared decision aid supports informed, appropriate uptake of the perioperative regimen it co-developed.

  • Astellas Pharmacompany

    Co-developer of enfortumab vedotin (with Pfizer); benefits when eligible patients understand and opt into the regimen's quantified survival advantage.

Research it builds on

  1. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
    Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr et al. · 2026 · 113 citations
    All ideas from this paper →
Leave feedback
feasibility